MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION:
Journal of Molecular Diagnostics September 2019 Volume 21, Issue 5, Pages 808–823.

AUTHORS:
Lorenza Mittempergher, Leonie J.M.J. Delahaye, Anke T. Witteveen, Jacob B. Spangler, Fariet Hassenmahomed, Sammy Mee, Soufiane Mahmoudi, Jiang Chen, Simon Bao, Mireille H.J. Snel, Sandra Leidelmeijer, Naomi Besseling, Anne Bergstrom Lucas, Carlos Pabón-Peña, Sabine C. Linn, Christa Dreezen, Diederik Wehkamp, Bob Y. Chan, René Bernards, Laura J. van ‘t Veer, Annuska M. Glas

SUMMARY:
The technical translation of MammaPrint and BluePrint tests from Microarray to NGS.

kevin2024-03-25T08:36:57-07:00September 1st, 2019|BluePrint, Evidence, MammaPrint, Other, Validation|

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

Kenyon Sweeney

Christy Garcia

PROF. LAURA VAN ‘T VEER, PhD

ROOPOM BANERJEE

Share This Story, Choose Your Platform!